FDA approves pricy new treatment for Alzheimer's: What you need to know - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Newswires RSS Get our newsletter
Order Prints
July 17, 2023 Newswires
Share
Share
Post
Email

FDA approves pricy new treatment for Alzheimer's: What you need to know

CBS - 3 WRBL (Columbus, GA)

(WGN Radio) – A new drug that shows promising results of slowing memory decline recently received the Food and Drug Administration's stamp of approval – but will anyone be able to afford it?

The FDA endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease. It works by clearing a sticky brain plaque linked to the disease, and it's the first medicine that's been convincingly shown to modestly slow the cognitive decline caused by Alzheimer's.

But Leqembi doesn't come cheap. It is priced at about $26,500 for a year's supply of IVs every two weeks.

"If we had to pay out of pocket, you'd certainly have to have substantial funds to do this," said Dr. Kevin Most, chief medical officer at Northwestern Central DuPage Hospital, in an interview with WGN Radio.

But the recent FDA approval paves the way for Medicare and other insurers to cover the drug.

Medicare administrator, Chiquita Brooks-LaSure, said the program will begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements, including enrollment in a federal registry to track the drug's real-world safety and effectiveness.

"I look at it and say it's our opportunity to prove that the drug is really working well. It will advance the other five, six, seven drugs that are in the pipeline right now that are doing similar things to remove that beta amyloid from the brain," said Dr. Most.

Even ignoring cost or insurance coverage, not every person with Alzheimer's will be able to get their hands on the drug. Doctors will need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it.

"When you look at the 6.5 million people with Alzheimer's, it's going to come down to a classification of probably between 1 to 2 million individuals will be available – or will be allowed – to do it," said Dr. Most. "Because we're looking at those with the early stages of Alzheimer's, the minor symptoms, to see if we can stop it in its tracks."

Leqembi's drugmaker Eisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026.

Eisai studied the drug in people with early or mild disease who were evaluated using a scale measuring memory, thinking and other basic skills. After 18 months, those who got Leqembi declined more slowly — a difference of less than half a point on the scale — than participants who received a dummy infusion. Some Alzheimer's experts say that delay is likely too subtle for patients or their families to notice.

Hear more from Dr. Most in the audio player below:

The Associated Press contributed to this report.

Older

Fight over gender-affirming care moves to HHS spending bill

Newer

Ron DeSantis keeps explaining away old Social Security, Medicare stances

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Health/Employee Benefits News

  • EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
  • THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
  • Grand jury accuses veteran of making false disability claims that defrauded VA
  • States push short-term insurance as healthcare costs climb
  • Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
More Health/Employee Benefits News

Life Insurance News

  • FORMER PRINCE GEORGE'S COUNTY INSURANCE AGENT SENTENCED FOR FELONY INSURANCE THEFT SCHEME
  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.